Angeion Corporation (NASDAQ: ANGN) announced today that William J.
Kullback has joined the company as Senior Vice president and Chief
Financial Officer, effective immediately. He replaces Dale H. Johnson,
63, who retired last month.
"With Bill’s
appointment as Chief Financial Officer, we have taken an important step
in the evolution of Angeion Corporation,” said
Rodney A. Young, President and Chief Executive Officer. "Bill’s
deep background in the medical device industry, combined with his
expertise in public company finance, experience in mergers and
acquisitions, his experience with both large and small organizations and
previous success in building an investor following, make him an ideal
addition to Angeion’s executive team.”
Kullback, 48, brings almost 25 years of financial and management
experience to Angeion Corporation. Most recently he was CFO of Flex Fund
Financial Services, a private financial services firm. Prior to that
Kullback served as CFO for IntriCon Corporation, a $50 million publicly
traded manufacturer that specializes in the high technology medical
device and communications industries. Kullback brings additional public
company experience to Angeion, gained from his tenures as CFO at
MedSource Technologies, Inc., a medical device outsourcer, and PEMSTAR,
Inc., a $700 million engineering and manufacturing service corporation,
where he was responsible for all finance, treasury, accounting,
reporting, tax, and mergers and acquisitions.
Further, Kullback served on the board of directors of Reptron
Electronics, Inc., where he was chairman of the audit committee and
involved in the sale of this publicly traded electronics manufacturing
services firm. Earlier in his career he worked at what is now
PricewaterhouseCoopers. Kullback received his Master of Business
Administration in accounting and his Bachelor of Arts from the State
University of New York at Buffalo.
"I am excited about the opportunity to join
the Angeion senior management team as a contributor toward the Company’s
continued success,” said Kullback. "I
look forward to leading the finance group and telling the Angeion story
to the investment community. Angeion has a bright future with new
product and program opportunities across multiple markets, including an
enhanced focus on international expansion, physician offices and
commercial fitness. I am pleased to help build this business.” About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics
Corporation in December 1999. Medical Graphics develops, manufactures
and markets non-invasive cardiorespiratory diagnostic systems that are
sold under the MedGraphics (www.medgraphics.com)
and New Leaf (www.newleaffitness.com)
brand and trade names. These cardiorespiratory diagnostic systems have a
wide range of applications in healthcare as well as health and fitness.
The Company’s products are sold
internationally through distributors and in the United States through a
direct sales force that targets heart and lung specialists located in
hospitals, university-based medical centers, medical clinics and
physicians’ offices, pharmaceutical
companies, medical device manufacturers, clinical research
organizations, health and fitness clubs, personal training studios, and
other exercise facilities. For more information about Angeion, visit www.angeion.com.
The discussion above contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements by their nature involve substantial risks and uncertainties.
Our actual results may differ materially depending on a variety of
factors including: (i) our ability to successfully operate our business
including our ability to develop, improve, and update our
cardiorespiratory diagnostic products and successfully sell these
products into existing and new markets, (ii) our ability to achieve
constant margins for products and consistent and predictable operating
expenses in light of variable revenues from our clinical research
customers, (iii) our ability to effectively manufacture and ship
products in required quantities to meet customer demands, (iv) our
ability to successfully defend ourselves from product liability claims
related to our cardiorespiratory diagnostic products and claims
associated with our prior cardiac stimulation products, (v) our ability
to protect our intellectual property, (vi) our ability to develop and
maintain an effective system of internal controls and procedures and
disclosure controls and procedures, and (vii) our dependence on
third-party vendors.
Additional information with respect to the risks and uncertainties faced
by the Company may be found in, and the above discussion is qualified in
its entirety by, the other risk factors that are described from time to
time in the Company’s Securities and Exchange
Commission reports, including the Annual Report on Form 10-K for the
year ended October 31, 2007.
Bookmarken
